Global Antihypertensive Drugs Market Overview
Antihypertensive Drugs Market Size was valued at USD 24.33 billion in 2023. The Antihypertensive Drugs market is projected to grow from USD 25.09 Billion in 2024 to USD 32.06 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.99% during the forecast period (2024 - 2032).The increase in the prevalence of hypertension and the expansion is the growing awareness of the complications are the key market drivers enhancing the market growth.
Antihypertensive Drugs Market Trends
- The increase in the prevalence of hypertension boosts the market growth
A long-term medical condition known as hypertension is characterized by persistent blood pressure in the arteries. Antihypertensive medications treat patients with high blood pressure, also called hypertension. Major disorders like hypertension come with serious side effects like heart attacks, heart failure, and dementia. Thus, early diagnosis and treatment of hypertension are necessary. Diuretics, ACE inhibitors, and vasodilators are a few of the medications that are used to treat hypertension.
The increase in the prevalence of hypertension around the world is one of the factors influencing the growth of the antihypertensive drugs market. An additional important factor driving the market's expansion is the growing awareness of the complications of high blood pressure. In addition, the market is growing as the number of older adults and sedentary behavior rise. But it's anticipated that recent patent expirations will impede the expansion of the antihypertensive market. On the other hand, the expansion of antihypertensive drug research is anticipated to present profitable opportunities during the forecast period. The prevalence of hypertension has been observed to increase significantly over the past few years due to the main known causes of hypertension, which include kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular diseases.
Additionally, some medications can cause hypertension in people with other illnesses or disorders, which is anticipated to aid in the market under study's expansion. A total of 1 point 13 billion people worldwide have hypertension, with two-thirds of them residing in low- and middle-income nations, according to the World Health Organization's most recent data, updated in May 2021. In a report titled "A View on Prevalence of Hypertension and Human Development Index," released in June 2020, researchers looked at the relationship between the prevalence of hypertension and HDI. They found that it varied between 35 and 41 percent in 182 nations. Thus, the market for anti-hypertensive drugs is anticipated to grow due to the rising prevalence of hypertension.
Growing initiatives by private and governmental organizations and increasing awareness of hypertension Globally are some additional factors that will support the growth of the anti-hypertensive drug market has enhanced the Antihypertensive Drugs market CAGR Globally in recent years.
Antihypertensive Drugs Market Segment Insights
Antihypertensive Drugs Therapeutic Class Insights
Based on Therapeutic Class, the Antihypertensive Drugs market segmentation includes Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, and Others. The ARBs segment held the majority share in 2022 contribution concerning the Antihypertensive Drugs market revenue. During the forecast period, the angiotensin receptor blockers segment will dominate the antihypertensive drugs market. The segment is expected to grow at a high CAGR from 2024 to 2032. Angiotensin II receptor blockers (ARBS) have a similar effect to ACE inhibitors, another type of blood pressure drug, but work in a different.
Antihypertensive Drugs Type Insights
Based on type, the Antihypertensive Drugs market segmentation includes Primary Hypertension and Secondary Hypertension. Over the past ten years, hypertension has become a health concern. Children's salt intake in developed countries typically exceeds the amount advised. The developing world is experiencing a similar trend. In the first year of life, a positive sodium balance is required for growth; however, a high salt intake may have detrimental cardiovascular effects that positively impact market growth.
Figure 1: Antihypertensive Drugs Market, by Type, 2022 & 2030 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Antihypertensive Drugs Distribution Channel Insights
Distribution Channels have bifurcated the Antihypertensive Drugs market data into Retail Pharmacies, Hospital Pharmacies, E-commerce Websites, Online Drug Stores, and Others. The Hospital Pharmacies segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. The increase in hospitals around the world is to blame for this. Additionally, this market segment is growing faster because antihypertensive medications require a prescription and are typically prescribed by trained medical professionals in hospitals. However, due to the increase in internet usage, the e-commerce segment is anticipated to grow the fastest during the forecast period.
Antihypertensive Drugs Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Antihypertensive Drugs market accounted for USD 10.0302 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Due to the high prevalence of hypertension and diseases that cause it in the region, North America currently holds a significant share of the market for anti-hypertensive drugs. It is anticipated to exhibit a similar trend over the forecast period. Other important market factors for the North American anti-hypertension market include the need for rapid and accurate diagnosis and treatment of hypertension, identifying those predisposed to the condition, the presence of technologically advanced healthcare infrastructure, and managing the disease's prognosis.
The United States will continue dominating the anti-hypertensive medications market in North America. The main factor driving the expansion of the market for anti-hypertensive medications in the United States is the rising prevalence of hypertension. The Centers for Disease Control and Prevention estimate that in July 2022, there will be 116 million adults who have hypertension, or 47% of the population. As a result, the rising prevalence of hypertension in the US is predicted to increase demand for anti-hypertensive medications, which will drive market expansion.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ANTIHYPERTENSIVE DRUGS MARKET SHARE BY REGION 2022 (%) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe’s Antihypertensive Drugs market accounts for the second-largest market share due to growing initiatives by private and governmental organizations and increasing awareness of hypertension globally. These are additional factors that will support the growth of the anti-hypertensive drug market. Further, the Germany Antihypertensive Drugs market held the largest market share, and the UK Antihypertensive Drugs market was the fastest-growing market in the European region.
The Asia-Pacific Antihypertensive Drugs Market is expected to grow at the fastest CAGR from 2022 to 2030. The Asia Pacific market is anticipated to grow more quickly over the forecast period due to growing hypertension awareness and the use of hypertensive medications. The booming biotechnology, pharmaceutical, and life science industries should be advantageous to develop nations like India, China, and Malaysia. For instance, according to the India Brand Equity Foundation (IBEF), the country's domestic pharmaceutical market will increase from its current estimated value of USD 42 billion to approximately USD 120 billion by 2021. Moreover, China’s Antihypertensive Drugs market held the largest market share, and the India Antihypertensive Drugs market was the fastest-growing market in the Asia-Pacific region.
Antihypertensive Drugs Key Market Players & Competitive Insights
Major market players are spending much on R&D to increase their product lines, which will help the Antihypertensive Drugs market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Antihypertensive Drugs industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Antihypertensive Drugs industry to benefit clients and expand the market sector. In recent years, the Antihypertensive Drugs industry has provided medicine with some of the most significant benefits. In the Antihypertensive Drugs markets, major players such as Sanofi S.A., Takeda Pharmaceuticals Company Limited, Boehringer Ingelheim, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited Inc., Daiichi Sankyo Company Limited, Astra Zeneca plc, Acetelion Ltd, and others are working on expanding the market demand by investing in research and development activities.
Sanofi S.A., Scientific advancements take time and effort. However, our desire to find solutions for patients drives us to create ground-breaking drugs and vaccines. Likewise, never give in. Reinvention is ingrained in our DNA and reflects our commitment to improving the lives of patients, partners, communities, and our people. This commitment can be seen throughout history as a local French enterprise and today as a top healthcare provider. As a single organization today, we are motivated by a shared ambition and purpose. For millions of people worldwide, our cutting-edge manufacturing and science, powered by data and digital technologies, have the power to transform the practice of medicine. Progress unites us and motivates us to advance individually and as a group.
Also, Ranbaxy Laboratories Limited Inc. Ranbaxy Laboratories Ltd. was established as a public company on June 16, 1961. It is registered with the Chandigarh Registrar of Companies and is categorized as a Non-Government Company. It has a paid up capital of Rs. 2,128,317,440 and an authorized share capital of Rs. 3,000,000,000. It is essential to the production of other chemical products. The most recent Annual General Meeting (AGM) of Ranbaxy Laboratories Ltd. took place on July 28, 2014. The most recent balance sheet submitted to the Ministry of Corporate Affairs (MCA) was on March 31, 2014.
Key Companies in the Antihypertensive Drugs market include
Antihypertensive Drugs Industry Developments
November 2020:Bystolic (Nebivolol), an anti-hypertensive medication, was once patented by AbbVie, the parent company of Allergan. A beta blocker called nebivolol treats heart failure and high blood pressure.
November 2020:The patent for Bystolic (Nebivolol), an anti-hypertensive medication, was lost by AbbVie, the parent company of Allergan. A beta blocker called nebivolol treats heart failure and high blood pressure.
September 2020:According to Glenmark Pharmaceuticals, the Association of Physicians of India (API) and the Hypertension Society of India (HIS) support the hypertension awareness symbol. A hypertension awareness campaign was also launched in India in May 2022 by the Namya Smile Foundation (NSF). The organization held a camp where participants’ pressure was measured, and they were informed of the various effects of high blood pressure.
Antihypertensive Drugs Market Segmentation
Antihypertensive Drugs Therapeutic Class Outlook
-
Calcium Channel Blockers
-
Beta-adrenergic Blockers
-
Renin Inhibitors
-
ACE Inhibitors
-
Vasodilators
-
Diuretics
-
ARBs
-
Others
Antihypertensive Drugs Type Outlook
-
Primary Hypertension
-
Secondary Hypertension
Antihypertensive Drugs Distribution Channel Outlook
-
Retail Pharmacy
-
Hospital Pharmacy
-
E-commerce Websites
-
Online Drug Stores
-
Others
Antihypertensive Drugs Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 24.33 billion |
| Market Size 2024 |
USD 25.09 billion |
| Market Size 2032 |
USD 32.06 billion |
| Compound Annual Growth Rate (CAGR) |
3.99% (2024-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Therapeutic Class, Type, Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Sanofi S.A., Takeda Pharmaceuticals Company Limited, Boehringer Ingelheim, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited Inc., Daiichi Sankyo Company Limited, Astra Zeneca plc, Acetelion Ltd. |
| Key Market Opportunities |
Increase the prevalence of hypertension. |
| Key Market Dynamics |
The expansion is the growing awareness of the complications. |
Anti Hypertensive Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
The Global Antihypertensive Drugs market size was valued at USD 24.33 Billion in 2023.
The Global market is projected to grow at a CAGR of 3.99% during the forecast period, 2024-2032.
North America had the largest share of the Global market
The key players in the market are Sanofi S.A., Takeda Pharmaceuticals Company Limited, Boehringer Ingelheim, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited Inc., Daiichi Sankyo Company Limited, Astra Zeneca plc, Acetelion Ltd.
The ARB category dominated the market in 2022.
Primary Hypertension had the largest share in the Global market.
